Overdose deaths involving prescription opioids have increased 5-fold in the United States since 1999.1 Benzodiazepines are frequently involved in opioid-related overdoses. Concomitant use of benzodiazepines and opioids increases the risk of overdose and death.2 In response to rising coprescriptions,3 the US Food and Drug Administration issued a boxed warning on August 31, 2016, highlighting the risks of coprescribing opioids and benzodiazepines. Prior research examined trends before the warning3 and found a decrease in opioid prescribing after the March 2016 Centers for Disease Control and Prevention guideline.4 However, it is not known whether coprescriptions further declined significantly after the boxed warning. We provide the first national estimate of opioid and benzodiazepine coprescribing before and after the boxed warning, to our knowledge.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Zhang V, Olfson M, King M. Opioid and Benzodiazepine Coprescribing in the United States Before and After US Food and Drug Administration Boxed Warning. JAMA Psychiatry. 2019;76(11):1208–1210. doi:https://doi.org/10.1001/jamapsychiatry.2019.2563
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: